Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jan Zeidler

Showing results (1-10 of 73) with videos related to

Pageof 8
Sort By:
Drugs - Real World Outcomes|October 18, 2016
Claims Data Analysis of Tumor Necrosis Factor Inhibitor Treatment Dosing Among Patients with Rheumatoid Arthritis: A Systematic Review of MethodsGundula Krack, Henning Zeidler, Jan Zeidler
European Journal of Ageing|December 12, 2022
A systematic review to identify the use of stated preference research in the field of older adult careLea de Jong, Jan Zeidler, Kathrin Damm
The International Journal of Eating Disorders|March 10, 2025
Health Economic Evaluation of Cognitive-Behavioral Therapy for Adolescents With Binge-Eating Disorder in GermanyNicolas Pardey, Ricarda Schmidt, Jan Zeidler, et al.
Applied Health Economics and Health Policy|August 27, 2013
Cost effectiveness of paliperidone palmitate for the treatment of schizophrenia in GermanyJan Zeidler, Jörg Mahlich, Wolfgang Greiner, et al.
Health Economics Review|July 26, 2012
The costs of schizophrenia and predictors of hospitalisation from the statutory health insurance perspectiveJan Zeidler, Lara Slawik, Jochen Fleischmann, et al.
Zeitschrift Fur Evidenz, Fortbildung Und Qualitat Im Gesundheitswesen|January 23, 2026
Socioeconomic deprivation and survival among patients with non-small cell lung cancer (NSCLC): Investigation using population-based Clinical Cancer Registry data of Lower Saxony Germany) and discussion of worldwide evidenceAdrian Rohde, Mike Klora, Tonia Brand, et al.
The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care|November 24, 2016
Access, use, and challenges of claims data analyses in GermanySarah Neubauer, Kristine Kreis, Mike Klora, et al.
Deutsche Medizinische Wochenschrift (1946)|January 18, 2019
[Guideline-Orientated Prescription of Disease-Modifying Drugs in Patients with Rheumatoid Arthritis - an Analysis Based on Social Health Insurance Claims Data]Sarah Neubauer, Henning Zeidler, Roland Linder, et al.
Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz|July 14, 2021
[Healthcare expenditure and the impact of age: a detailed analysis for survivors and decedents]Jona T Stahmeyer, Sascha Hamp, Jan Zeidler, et al.
Health Economics Review|October 2, 2012
Biologic TNF inhibiting agents for treatment of inflammatory rheumatic diseases: dosing patterns and related costs in Switzerland from a payers perspectiveJan Zeidler, Thomas Mittendorf, Rüdiger Müller, et al.
Pageof 8

Showing results (1-10 of 73) with videos related to

Sort By:
Pageof 8
Drugs - Real World Outcomes|October 18, 2016
Claims Data Analysis of Tumor Necrosis Factor Inhibitor Treatment Dosing Among Patients with Rheumatoid Arthritis: A Systematic Review of MethodsGundula Krack, Henning Zeidler, Jan Zeidler
European Journal of Ageing|December 12, 2022
A systematic review to identify the use of stated preference research in the field of older adult careLea de Jong, Jan Zeidler, Kathrin Damm
The International Journal of Eating Disorders|March 10, 2025
Health Economic Evaluation of Cognitive-Behavioral Therapy for Adolescents With Binge-Eating Disorder in GermanyNicolas Pardey, Ricarda Schmidt, Jan Zeidler, et al.
Applied Health Economics and Health Policy|August 27, 2013
Cost effectiveness of paliperidone palmitate for the treatment of schizophrenia in GermanyJan Zeidler, Jörg Mahlich, Wolfgang Greiner, et al.
Health Economics Review|July 26, 2012
The costs of schizophrenia and predictors of hospitalisation from the statutory health insurance perspectiveJan Zeidler, Lara Slawik, Jochen Fleischmann, et al.
Zeitschrift Fur Evidenz, Fortbildung Und Qualitat Im Gesundheitswesen|January 23, 2026
Socioeconomic deprivation and survival among patients with non-small cell lung cancer (NSCLC): Investigation using population-based Clinical Cancer Registry data of Lower Saxony Germany) and discussion of worldwide evidenceAdrian Rohde, Mike Klora, Tonia Brand, et al.
The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care|November 24, 2016
Access, use, and challenges of claims data analyses in GermanySarah Neubauer, Kristine Kreis, Mike Klora, et al.
Deutsche Medizinische Wochenschrift (1946)|January 18, 2019
[Guideline-Orientated Prescription of Disease-Modifying Drugs in Patients with Rheumatoid Arthritis - an Analysis Based on Social Health Insurance Claims Data]Sarah Neubauer, Henning Zeidler, Roland Linder, et al.
Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz|July 14, 2021
[Healthcare expenditure and the impact of age: a detailed analysis for survivors and decedents]Jona T Stahmeyer, Sascha Hamp, Jan Zeidler, et al.
Health Economics Review|October 2, 2012
Biologic TNF inhibiting agents for treatment of inflammatory rheumatic diseases: dosing patterns and related costs in Switzerland from a payers perspectiveJan Zeidler, Thomas Mittendorf, Rüdiger Müller, et al.
Pageof 8